A Variety of Antibody/Peptide Discovery Services Provided by Creative Biolabs for Viral Vaccine Research

June 21 18:51 2021
Creative Biolabs is harnessing a powerful AntInfect™ Platform to promote anti-infective biomolecular discovery for various viral diseases. With decades of experience in antibody and antimicrobial peptide (AMP) discovery, Creative Biolabs now provides one-stop services on antibody/peptide discovery using state-of-the-art technology, aiming to help scientists around the world accelerate research into viral diseases.

New York, USA – June 21, 2021 – Viral diseases are extremely widespread infections caused by viruses, a type of microorganism. There are many types of viruses that cause a wide variety of viral diseases. Viruses cause familiar infectious diseases such as the common cold, flu, and warts. They also cause severe illnesses such as HIV/AIDS, Ebola, and COVID-19.

Treatment of viral infections varies depending on the specific virus and other factors. Antiviral medicines are available to treat some viral infections. Other treatments for viral infections, such as vaccines, can help prevent people from developing many viral diseases. Scientists around the world have been exploring the development of vaccines against different viruses. Antibodies are able to neutralize viruses before they infect a person. This unique ability has been a major focus of research, providing an excellent direction for vaccine discovery. As a pioneer in the field of virology, Creative Biolabs focuses on the discovery of novel anti-infective biomolecules and their application to problems in biology and medicine. More recent work has focused on antibody/peptide discovery for viral diseases, particularly SARS-CoV-2 and influenza viruses.

• Discovery of Neutralizing Antibody (NAb) and Peptide Targeting SARS-CoV-2

Although vaccines are available for the prevention of COVID-19, the SARS-CoV-2 has mutated in some areas. Neutralizing antibodies (NAbs) have always been a focus of research in vaccine development because NAbs-mediated protection can prevent the escape of mutant viruses from cytotoxic T-lymphocytes that are commonly associated with rapid disease progression and severity. In addition, functional peptides are considered to be a promising approach for controlling infections of SARS-CoV-2.

• Discovery of Broadly Neutralizing Antibody (BNAb) and Peptide Targeting Influenza Virus

There are two main types of influenza virus: Types A and B. The influenza A and B viruses routinely spread in people and are responsible for seasonal flu epidemics each year. New versions of the Influenza vaccines are developed twice a year, as the influenza virus rapidly changes. Therefore, the development of a universal vaccine and broadly neutralizing antibodies (BNAbs) is essential for controlling various mutant viruses. In addition, the Influenza A virus (IAV) remains a major threat that can cause severe morbidity and mortality due to rapid genomic variation. Antimicrobial peptides (AMPs) have been considered to be potential candidates for novel treatment against IAV infection.

As a participant in the comprehensive vaccine development process, Creative Biolabs’ advanced technologies and platforms help customers worldwide shorten development timelines and reduce manufacturing risks by providing reliable antibody/peptide discovery services for viral diseases. More information is available at www.creative-biolabs.com/antinfect.

About Creative Biolabs

With deep experience in the fields of anti-infective biomolecules and manufacturing sciences, the Creative Biolabs team came together to solve the scientific and technical hurdles that block access to antibody and antimicrobial peptide for viral diseases. The company’s focus and passion are to create access and value for a global market through scientific and technological innovation.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/antinfect